Yantai, September 27, 2023 - The results of a Phase I clinical trial comparing BA1102, a biosimilar candidate developed by Boan Biotech, with the reference drug denosumab (XGEVA®), were recently publi...
Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been administered to the first subject in a Phase I clinical trial. This makes BA1202 the first CEA/CD3 bispe...
Boan Biotech (6955.HK) announced its 2023 half year results and recent developments on August 27, 2023.Highlights of 2023 half year resultsRobust revenue growthIn the first half of 2023, the company&r...
Follow me
鲁公网安备37069102000284